<scp>One‐year</scp> mortality and consequences of <scp>COVID</scp>‐19 in cancer patients: A cohort study

Chai, Changchun; Feng, Xiaojun; Lü, Meixia; Li, Shoupeng; Chen, Kui; Wang, Hongxiang; Wang, Wendan; Tang, Zhaoming; Cheng, Gang; Wu, Xiaoxiong; Li, Yunfeng; Wen, Yuying; Da, Banghong; Fan, Hong; Wang, Lei; Ai, Fen; Li, Wei; Cao, Peng; Zhang, Hongrong; Wen, Shifeng; Jin-nong, Zhang; Weng, Yuxiong; Tang, Zehai

doi:10.1002/iub.2536

Cited by 41 publications

(40 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the limited number of patients involved in our work, our data confirm the impairment in the viral clearance in patients affected by hematological neoplasms, and the importance of early viral clearance on clinical outcome and overall survival. Patients who did not develop seroconversion after COVID-19 vaccination had higher probability of achieving viral clearance by 14 days, an independent predictor of overall survival at one year for unvaccinated patients [ 2 , 50 , 57 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection

Romano

Cerchione

Conticello

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Clinical course of COVID-19 depends on several patient-specific risk factors, including immune function, that is largely compromised in cancer patients. Methods: We prospectively evaluated 120 adult consecutive patients (including 34 cases of COVID-19 breakthrough after two full doses of BNT162b2 vaccine) with underlying hematological malignancies and a SARS-CoV-2 infection, in terms of patient’s clinical outcome. Results: Among fully vaccinated patients the achievement of viral clearance by day 14 was more frequent than in unvaccinated patients. Increased 30-day mortality was associated with presence of active/progressing disease and absolute monocyte count lower than 400 cells/uL. Results of multivariable analysis in unvaccinated patients showed that the pre-infection absolute count of monocytes less or equal to 400 cells/mmc, active or progressive disease of the underlying hematological malignancy, the COVID-19 severity identified by hospitalization requirement and lack of viral clearance at 14 days were independent predictors of 1-year overall survival. Conclusions: Taken together, our results indicate that absolute monocyte count determined one month before any documented SARS-CoV-2 infection could identify patients affected by hematological neoplasms with increased risk of inferior overall survival.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In most cases, COVID-19 symptoms are moderate or totally absent, with about one week of incubation period. Around 15% of patients can progress to severe pneumonia and about 5% eventually progress to acute respiratory distress pneumonia, renal failure, septic shock, multiple organ failure and death [ 2 , 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection

Romano

Cerchione

Conticello

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Table 1 outlines the significant findings with regard to changes in outcomes of patients with solid and/or haematologic malignancies following COVID-19 infection. 3 , 5 , 7 , 21 , 22 , 29 , 57–108 …”

Section: Introductionmentioning

confidence: 99%

“…In studies that included solid cancer patients, those who got COVID-19 had a higher probability of death compared with patients without cancer. 7 , 57 , 60 Several risk factors for increased mortality have been identified, including advanced age, male sex, smoking history, metastatic cancer, the presence of lung or bone metastases, higher C-reactive protein levels, the number of comorbidities and poor performance status. 7 , 21 Some studies found the age cut-off for worse prognosis to be 65 y, 96 while others found it to be 75 y.…”

Section: Introductionmentioning

confidence: 99%

“…Those with lung, digestive (excluding colorectal), nasopharyngeal, brain and skin cancers had high mortality, with lung cancer as the highest. 7 , 57 , 101 Moderately higher mortality was noted with genitourinary, female genital tract, breast and thyroid cancers. 57 One study found genitourinary malignancies to not have a higher risk for mortality compared with the general population 91 and another found those with gynaecologic cancer to have a similar age-specific mortality risk.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 in cancer patients

Seneviratne

Wijerathne

Yasawardene

et al. 2022

Transactions of the Royal Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has currently affected >220 million individuals worldwide. The complex interplay of immune dysfunction, active malignancy, the effect of cancer treatment on the immune system and additional comorbidities associated with cancer and COVID-19 all affect the outcomes of COVID-19 in patients with cancer. We have discussed the published findings (through the end of September 2021) on the effects of cancer on the morbidity and mortality of COVID-19, common factors between cancer and COVID-19, the interaction of cancer and COVID-19 treatments, the impact of COVID-19 on cancer clinical services, immune test findings in cancer patients with COVID-19 and the long-term effects of COVID-19 on cancer survivors.

show abstract

Challenges posed by COVID‐19 in cancer patients: A narrative review

et al. 2021

View full text Add to dashboard Cite

A novel coronavirus, or severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), was identified as the causative agent of coronavirus disease 2019 (COVID‐19). In early 2020, the World Health Organization declared COVID‐19 the sixth public health emergency of international concern. The COVID‐19 pandemic has substantially affected many groups within the general population, but particularly those with extant clinical conditions, such as having or being treated for cancer. Cancer patients are at a higher risk of developing severe COVID‐19 since the malignancy and chemotherapy may negatively affect the immune system, and their immunocompromised condition also increases the risk of infection. Substantial international efforts are currently underway to develop specific methods for diagnosing and treating COVID‐19. However, cancer patients’ risk profiles, management, and outcomes are not well understood. Thus, the main objective of this review is to discuss the relevant evidence to understand the prognosis of COVID‐19 infections in cancer patients more clearly, as well as helping to improve the clinical management of these patients.

show abstract

One‐year mortality and consequences of COVID‐19 in cancer patients: A cohort study

Abstract: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as

Cited by 41 publications

References 21 publications

Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection

Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection

COVID-19 in cancer patients

Challenges posed by COVID‐19 in cancer patients: A narrative review

Contact Info

Product

Resources

About